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Abstract
To better understand how medication status and task demands affect cognition in Major
Depressive Disorder (MDD), we evaluated medication-naïve patients with MDD, medicated
patients with MDD receiving the Selective Serotonin Reuptake Inhibitors (SSRI) paroxetine, and
healthy controls. All three groups were administered a computer-based cognitive task with two
phases, an initial phase in which a sequence is learned through reward-based feedback (which our
prior studies suggest is striatal-dependent), followed by a generalization phase that involves a
change in the context where learned rules are to be applied (which our prior studies suggest is
hippocampal-region dependent). Medication-naïve MDD patients were slow to learn the initial
sequence but were normal on subsequent generalization of that learning. In contrast, medicated
patients learned the initial sequence normally, but were impaired at the generalization phase. We
argue that these data suggest (i) an MDD-related impairment in striatal-dependent sequence
learning which can be remediated by SSRIs and (ii) an SSRI-induced impairment in hippocampal-
dependent generalization of past learning to novel contexts, not otherwise seen in the medication-
naïve MDD group. Thus, SSRIs might have a beneficial effect on striatal function required for
sequence learning, but a detrimental effect on the hippocampus and other medial temporal lobe
structures critical for generalization.
Keywords
Major Depressive Disorder; Selective Serotonin Reuptake Inhibitor (SSRI); hippocampus; basal
ganglia; reward; punishment; sequence learning; context-shift; generalization
1. INTRODUCTION
Major depressive disorder (MDD) is a condition characterized by a long-lasting depressed
mood or marked loss of interest or pleasure in all or nearly all activities (Belmaker and
Agam, 2008). Relatively little is known about the effects of MDD on striatal-based learning,
although it is well known that the striatum is a key brain region disrupted in MDD (Dunlop
and Nemeroff, 2007; Nestler and Carlezon, 2006; Nutt, 2006; Perona et al., 2008).
Converging evidence from the literature confirms the involvement of the broader basal
ganglia dopaminergic system in the pathophysiology and cognitive changes related to MDD.
For example, recent imaging studies suggest that patients with MDD show cognitive and
neurochemical dysfunction directly related to the nigrostriatal system (Dunlop and
Nemeroff, 2007; Robinson et al., 2012; Walter et al., 2007). In addition, the major symptom
of MDD, anhedonia, has been linked to dopaminergic dysfunction in the basal ganglia
(Bressan and Crippa, 2005; Dhillon et al., 2008; Heinz et al., 1999; Miller et al., 1996;
Schmidt et al., 2001). Further, patients with MDD have a three-fold higher than normal risk
of developing Parkinson’s disease (PD) (Leentjens et al., 2003; Schuurman et al., 2002), in
which nigrostriatal dopaminergic neurons decay (Kish et al., 1988). Finally, studies have
reported reductions in the size of the striatum in patients with MDD (Lorenzetti et al., 2009)
that has been linked to impairments in motor sequence learning (Naismith et al., 2006).
However, because psychomotor retardation is a common feature of MDD (Buyukdura et al.,
2011), it is unclear whether such deficits reflect learning deficits or just motor slowing. The
present study addresses this issue by using a computer-based test of sequence learning
(Shohamy et al., 2005; Nagy et al., 2007a). In this task, participants learn to execute a chain
sequences leading to reward. The chain is gradually lengthened until a complete sequence in
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learned. Subjects are first trained to learn A→reward, followed by B→A→reward, and so
forth until a full sequence is acquired (D→C→B→A→reward). Learning is evaluated by the
number of errors that are committed at each stage of the task, and therefore, learning does
not dependent on response speed. Converging evidence from the literature suggests that the
basal ganglia dopaminergic system is vital for this type of reward-based sequence learning
(Haber and Knutson, 2010; Schultz, 1997). For example, a previous study from our group
utilizing the same task as in the current study showed that medication-naïve patients with
PD were significantly impaired on sequence-learning (Nagy et al., 2007a). A different study
showed that dopaminergic medication (L-dopa) remediated this deficit (Shohamy et al.,
2005).
The task also contains a subsequent generalization phase, designed to test the generalization
of learned stimulus-response associations. In this phase, subjects are presented with a choice
between the door that was previously correct in this room, a door that was previously-correct
in a different room, and a “distractor” door that was never correct in any room. To
successfully pass this phase, subjects are required to apply their previously learned door-
room associations from the sequence-learning phase to new contexts with novel distractors.
Animal and human work has shown that the medial temporal lobe plays an important role in
generalization of learning over multiple contexts (Eichenbaum et al., 1996; Myers et al.,
2002; Myers et al., 2003). Specifically, a previous study using this task found that PD
patients with nigro-striatal dysfunction (but presumed intact medial temporal lobe function)
showed no impairment in generalization, while those with amnestic mild cognitive
impairment (aMCI, and presumed medial temporal lobe dysfunction) did show an
impairment (Nagy et al., 2007a), consistent with the view that the reward-based sequence
learning phase is striatal-dependent while the subsequent generalization phase is
hippocampal/medial temporal lobe dependent. This finding is important because patients
with MDD are also thought to have a smaller-than-average hippocampus, a key brain region
for memory formation located within the medial temporal lobe (Campbell and Macqueen,
2004; MacQueen et al., 2003; Vakili et al., 2000; Vythilingam et al., 2004). Moreover,
studies indicate that medication-free patients with MDD are impaired on hippocampal-
dependent memory measures such as the delayed paragraph recall of Wechsler Memory
Scale and the Selective Reminding Test (Austin et al., 2001; Vythilingam et al., 2004).
Thus, we seek to address how MDD influences hippocampal-based generalization, in
addition to striatal-based sequence learning.
Of note, a previous study on this task found a sequence-learning deficit but spared
generalization in patients with MDD (Polgar et al., 2007). However, this experiment did not
control for medication use and so it is still not clear how antidepressants affect cognitive
performance. It has been hypothesized that selective serotonin reuptake inhibitors (SSRIs)
achieve their therapeutic mood-enhancing effect, in part, by modifying synaptic availability
of serotonin, by enhancing dopaminergic function in the brain (Nutt, 2006), and possibly
also by enhancing neurogenesis in the hippocampal region (Malberg, 2004). Neuroimaging
and animal studies suggest that SSRIs increase the size of the hippocampus by augmenting
the rate of neurogenesis in the dentate gyrus, a substructure of the hippocampal region
(Boldrini et al., 2009; Malberg and Schechter, 2005; Sahay et al., 2011). Furthermore, it has
been shown in animal studies that neurogenesis in the dentate gyrus is key for the mood
augmenting effect of antidepressants (David et al., 2009), although the blockage of
neurogenesis does not induce depression-like behavior in animals (Santarelli et al., 2003).
However, it has not been sufficiently tested what SSRIs would do for medial temporal lobe
dependent learning using sensitive measures of cognitive function similar to the task we use
in our current study. SSRI-induced neurogenesis could indicate a learning improvement with
SSRIs. However, past studies showed ambiguous effects of SSRIs on medial temporal lobe
Herzallah et al. Page 3
J Affect Disord. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
dependent processes (Carlini et al., 2012; Igelstrom and Heyward, 2012; Sass and
Wortwein, 2012; Vythilingam et al., 2004),
Thus, it remains unclear how MDD and medication use influences cognitive function on a
learning and generalization task. To our knowledge, few studies have conducted thorough
assessments of striatal- and hippocampal-dependent learning-and-memory function on
patients with MDD both with and without SSRI treatment. In our current study, we
investigate the cognitive correlates of striatal and hippocampal function in two groups of
patients with MDD, those that are medication-naïve and those that have been treated using
SSRIs, as well as healthy matched controls. We predicted that medication-naïve patients
with MDD would resemble medication-naïve patients with PD, being impaired at initial
sequence learning, whereas SSRI treated patients would not show this impairment. Given
past studies showing ambiguous effects of SSRIs on medial temporal lobe dependent
processes (Carlini et al., 2012; Igelstrom and Heyward, 2012; Sass and Wortwein, 2012;
Vythilingam et al., 2004), it was not clear a priori what, if any, effect SSRIs would have on
the generalization phase of this task. As described below, our results indicated that while
patients treated with SSRIs did not reveal an MDD-derived sequence-learning deficit, these
medications led to an additional and heretofore, novel impairment in the medial temporal
lobe dependent generalization of this learning.
2. METHODS
2.1 PARTICIPANTS
We recruited 16 medication-naïve patients with MDD (MDD), 15 SSRI-responding patients
with MDD (MDD-T), and 25 HC subjects, from various psychiatric clinics, mental health
care centers and primary health care centers throughout the West Bank, Palestinian
Territories. All subjects were Caucasians, ranging from 18–60 years of age. Participants
were group matched for age, gender and years of education, as shown in Table 1. All
subjects underwent screening evaluations that included a medical history and a physical
examination. Psychiatric assessment was conducted using an unstructured interview with a
psychiatrist using the DSM-IV-TR criteria for the diagnosis of MDD, and the Mini
International Neuropsychiatric Interview (MINI) (Amorim et al., 1998). All SSRI-treated
patients with MDD received 10–30 mg of paroxetine per day (M=16.67, SD=7.78) as part of
their normal ongoing treatment. Inclusion criteria for HC subjects were absence of any
psychiatric or other disorders that might affect cognition. MDD-T patient average exposure
to SSRIs was 35.35 (SD=43.96) months. MDD-T patients’ response to SSRIs was assessed
using subjective reports and scores on the Beck Depression Inventory II. Exclusion criteria
for all subjects included psychotropic drug exposure, except for the SSRI paroxetine in the
SSRI-treated MDD group; major medical or neurological illness; illicit drug use or alcohol
abuse within the past year; lifetime history of alcohol or drug dependence; psychiatric
disorders other than major depression (excepting comorbid anxiety symptoms); current
pregnancy or breastfeeding. After receiving a complete description of the study, participants
provided written informed consent as approved by the Al-Quds University Ethics
Committee and the Rutgers Institutional Review Board.
2.2 NEUROPSYCHOLOGICAL TEST BATTERY
All subjects completed the Arabic version (Inzelberg et al., 2007) of a battery of
neuropsychological test questionnaires: Mini-Mental Status Examination (MMSE (Folstein
et al., 1975)), Beck Depression Inventory II (BDI-II) (Beck et al., 1996), Beck Anxiety
Inventory (BAI) (Beck et al., 1988) and the digit span subtest of the Revised Wechsler Adult
Intelligence Scale (WAIS-R digit span) (Burgess et al., 1992). All results are summarized in
Table 1. One-way ANOVAs, with a Bonferroni correction of α=0.005 to protect the level of
Herzallah et al. Page 4
J Affect Disord. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
significance (9 comparisons), revealed a significant effect of group on BDI-II
(F(2,53)=79.65, p<0.001, η2=0.75), BAI (F(2,53)=17.90, p<0.001, η2=0.40) and WAIS-R
scores (F(2,53)=9.22, p<0.001, η2=0.26). For WAIS-R, there was a significant difference
between HCs and both MDD groups (p<0.05). However, BDI-II and BAI scores were
significantly correlated. Further, only BDI-II scores significantly correlated to behavioral
task results. Hence, we only included BDI-II as a covariate in the analysis of cognitive data
(for more details, please see Figure 3-A).
2.3 COMPUTER-BASED COGNITIVE TASK
2.3.1 Sequence Learning Followed by Generalization with a Context-Shift—The
task as previously reported (Shohamy, Bodi). It was run on a Macintosh computer,
programmed in the SuperCard language. In this task, participants are instructed to guide an
animated character (nicknamed “Kilroy”) through a sequence of four rooms with different
colored doors to reach a goal point, the outside world. The rooms have a uniform white
background, and are drawn using perspective lines, with three black doors appearing on the
far wall. The doors appear about 2″ high, and the colored cards are each 1″ high by 0.5″
wide, and outlined in white for visual clarity. The animated figure (Kilroy) appears about 2″
tall.
On each trial, Kilroy appears in a room with three doors, each of which has a colored card
(see Figure 1-A). The three colored cards in each room are consistent for every participant,
but no color appears in more than one room during training. For example, room A might
have red, green, and purple doors; room B might have yellow, blue, and brown doors, and so
on. The colored cards marking the doors in each of six rooms are selected from a set of
eighteen unique and highly discriminable colors. Assignment of colors was randomized
across subjects. Spatial layout of these three colored cards on the doors (left, center, right)
was randomized on each trial, so that the correct answer (left, center, right) varied across
trials in a room. Thus, the color of the card, not the location of the door, determines the
correct response on each trial.
In each room, the subject uses the computer mouse to move the cursor to click on one of the
doors. When the subject selects a door, Kilroy turns, walks to the door, and tries to open it.
If the subject’s choice is incorrect, the door is “locked” and Kilroy cannot open it. He puts
his hands on his hips and makes a disappointed face, and the word “Locked!” appears on the
bottom of the screen (Figure 1-C). Kilroy then moves back to the center of the room, and
awaits the subject’s next choice. If the subject’s choice is correct, Kilroy opens the door and
steps through. If this room was at the end of the sequence, Kilroy reaches the outside, where
he turns and gives a thumbs-up sign (Figure 1-B); if the room was at an earlier stage of the
sequence, Kilroy steps through into the next room (Figure 1-D) and, once there, waits for
further instructions (as in Figure 1-A). In either case (correct or incorrect response), the
outcome appears on the screen for 1 s; there is then a 0.33 s interval before Kilroy appears at
the bottom of the screen again, ready for new instructions. There is no limit on response
times.
One trial consists of Kilroy traversing a full sequence of rooms until (eventually) reaching
the outside. The length of this sequence increases from one to four rooms over the course of
training, starting in the room leading directly to the outside world and progressively moving
further away. A trial is scored as correct if the subject chooses the correct door on the first
opportunity for every room in the sequence. However, a subject may make one or more
errors on a trial, by choosing an incorrect door one or more times before choosing the
correct door, in each of one or more rooms in the sequence. This means that a subject could
make more than one error per trial. Each learning phase continues until the subject
completes four consecutive correct trials or to a maximum of fifteen trials. If a subject fails
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to reach criterion within the maximum number of trials for any phase, that phase is
terminated, further training and context-shift phases are skipped, and the subject proceeds
directly to the last (retraining) phase of the task.
2.3.2 Procedure—The subject is seated in a quiet testing room at a comfortable viewing
distance from the screen. Before the test, the subject is informed that the aim of the game is
to help a cartoon figure get out of the house as many times as possible. The following
instructions appear: “Welcome to the experiment. In this experiment, you will see a
character named Kilroy who is trying to get out of the house. Each room in the house has
three doors, and each door has a colored card on it. On each trial, two of the doors are
locked, and one door is unlocked. In each room, click on the color card of the door that you
think is unlocked. If you are correct, Kilroy will get outside. Good luck!” The task then
consisted of the following phases (table 2):
1. Practice. The Practice Room appears, with three colored doors (P1P2P3), and Kilroy
in his “waiting-for-instructions” position at the front bottom of the screen. If the
subject chooses the correct door (P1), Kilroy makes it outside and the trial is
concluded. Every trial terminates with Kilroy (eventually) reaching the outside.
The practice phase continues until the subject makes four consecutive correct trials
(i.e. chooses the correct door on the first response in each of four trials).
2. Phase 1: Sequence training. At this point, new instructions appear: “You’ve
successfully finished practice! Now Kilroy will be put in some new rooms. Again,
in each room, two doors are locked and one door is unlocked. Each time, click on
the door that you think is unlocked. Sometimes, Kilroy will have to go through
more than one room to reach the outside. Good luck!” Kilroy now appears in his
“waiting-for-instructions” position in Room 1. This phase is identical to the
practice phase, except that three new colored cards are used (A1A2A3). Here,
subjects have to learn to open the correct door (A1, see Table 2). Once this is
learned, phase 2 begins, in which Kilroy appears in Room 2, which contains three
new colored cards; here, choice of the correct door (B1) leads Kilroy to Room 1,
where a correct answer leads him outside. Once this is learned, subjects work
through phase 3 (door C1 in Room 3 leads to Room 2 and so on) and phase 4 (door
D1 in Room 4 leads to Room 3 and so on) until, by the end of phase 4, subjects
should be choosing the correct door in each room: D1→C1→B1→A1→reward.
3. Phase 2: Generalization with Context-shift. Next comes a generalization with
context-shift phase, unsignaled to the subject. At the start of a trial, Kilroy appears
in Room 4. Correct responses will, as usual, allow him to progress through the
sequence of rooms and reach the outside. However, now the three cards include one
that was previously correct in that room, one that was previously correct but in a
different room, and a distractor that was never correct in any room. Thus, in Room
2, Kilroy might be presented with a choice between card B1, card A1, and card C3.
Card B1 is the correct choice, and should be chosen by a subject who had learned
the sequence, that is, what choice to make at each step in the sequence. But a
subject who had merely learned non-sequential stimulus-response associations
might choose A1, since that is a stimulus that had been directly associated with
reward in the past. The generalization with context-shift phase contains six trials,
each trial consisting of a trip through the usual four rooms. This phase enables
dissociation between subjects who learned the correct sequence (i.e., what choice to
make at each step in the sequence) versus subjects who merely learned non-
sequential stimulus-response associations (i.e., knowing a stimulus has been
associated with a reward regardless of the sequence).
Herzallah et al. Page 6
J Affect Disord. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. Phase 3: Retraining. The final phase is a retraining phase, in which subjects are
required to learn a new room with three new colored cards (Y1Y2Y3), one of which
leads directly to the outside. The purpose of this phase is to determine whether any
learning deficits observed on the sequence learning or generalization phase are due
to fatigue effects or other non-associative factors.
At the end of the test, the subject sees a screen reporting the total number of trials on which
Kilroy got out, which is equal to the total number of trials (regardless of intervening errors).
2.4 STATISTICAL ANALYSIS
The normality of data distribution was checked using Kolmogorov–Smirnov tests. All data
were normally distributed (p>0.1). Mixed-design ANCOVA using SPSS 20 was used to
compare HC subjects, medication-naïve and SSRI-treated patients with MDD, followed by
planned one-way ANOVAs and Tukey’s Honestly Significant Difference (HSD) post-hoc
tests. Pearson’s product–moment correlation coefficients were calculated between test
performance and neuropsychological measures. The level of significance was set at α=0.05.
3. RESULTS
Five participants failed to complete one of the steps of the sequence-learning phase within
the maximum allowed trials (2 HC, 2 medication-native MDD, and 1 SSRI-treated MDD).
Data from these subjects were excluded from subsequent analyses. The completion rate did
not differ among groups, χ2(2) = 0.37, p=0.83.
We conducted mixed-design ANCOVA, with group as the between-subject variable,
learning phase (sequence-learning, context-shift generalization and retraining) as the within-
subject variable, BDI-II results as a covariate (there was a significant correlation between
BDI-II scores, and the number of errors in the sequence-learning phase, see 3.4
Correlational Studies), and number of errors in sequence-learning, context-shift
generalization and retraining as the dependent variable.
Box’s test confirmed the equality of covariance matrices of dependent variables across
groups (Box’s M=18.371, F(12, 7458.903)=1.38, p=0.167). The ANCOVA revealed a
significant effect of group (F(2,47)=6.282, p=0.004, η2=0.211) and learning phase
(F(2,94)=16.018, p<0.001, η2=0.254). In addition, there was a significant interaction
between group and learning phase (F(4,94)=9.835, p<0.001, η2=0.295) as well as between
BDI-II scores and learning phase (F(4,94)=3.633, p=0.030, η2=0.072. Although there was a
significant correlation between BDI-II scores and the number of errors in the sequence-
learning phase, BDI-II did not have a significant effect on the between-subject effects of the
covariance analysis (p>0.05), and was dropped from subsequent analyses.
To further investigate the differences between groups and within phases, we conducted one-
way ANOVA on the sequence-learning, generalization and retraining phases separately,
with a Bonferroni correction of α=0.017 to protect the level of significance (for three
comparisons).
3.1 Phase 1: Sequence Learning
Using one-way ANOVA, with group as the independent variable, and the total number of
errors in the sequence-learning phase (A–D, see Table 2) as the dependent variable, we
found a significant effect of group (F(2,48)=8.64, p=0.001, η2=0.26). Tukey’s HSD post-hoc
test revealed that medication-naïve patients with MDD made significantly more errors than
either SSRI-treated patients with MDD or HCs (p<0.05, Figure 2-A).
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3.2 Phase 2: Generalization with Context-Shift
One-way ANOVA, with group as the independent variable, and the total number of errors in
the context-shift generalization phase as the dependent variable, revealed significant effect
of group (F(2,48)=10.60, p<0.001, η2=0.31). Follow up post-hoc analysis using Tukey’s
HSD showed that SSRI-treated patients with MDD made significantly more errors than
either medication-naïve patients with MDD or HCs (p<0.05, Figure 2-B).
3.3 Phase 3: Retraining
One-way ANOVA, with group as the independent variable, and the total number of errors in
the retraining phase as the dependent variable, showed no effect of group (F(2,48)=0.43,
p=0.64).
3.4 Correlational studies
Pearson’s product–moment correlation coefficients were calculated between test
performance on our sequence learning task and neuropsychological measures. There was a
significant correlation between BDI-II scores, and the number of errors in the sequence-
learning phase. Specifically, the more depressed subjects were, the worse they did at the
sequence-learning phase (Pearson’s r=0.360, N=51, p=0.009, Figure 3-A). However, the
same correlation did not hold significance when subjects were distributed to their
corresponding groups (HC: Pearson’s r=−0.054, N=23, p=0.808; medication-naïve MDD:
Pearson’s r=−0.346, N=14, p=0.225; SSRI-treated MDD: Pearson’s r=0.080, N=14,
p=0.787). The negative correlation between WAIS-R digit-span results, which represent a
measure of short-term memory, and the number of errors on the generalization phase,
approached significance; specifically, better working memory scores were associated with
better performance (fewer errors) on the generalization phase of the task (Pearson’s r=
−0.245, N=51, p=0.083, Figure 3-B). When subjects were split into groups, was that of HCs
and SSRI-treated patients with MDD correlation results were approaching significant (HC:
Pearson’s r=−0.360, N=23, p=0.092; medication-naïve MDD: Pearson’s r=0.226, N=14,
p=0.438; SSRI-treated MDD: Pearson’s r=0.462, N=14, p=0.096).
4. DISCUSSION
The present study investigated the effects of MDD and SSRI administration on sequence
learning phase and generalization. As predicted, medication-naïve patients with MDD were
impaired on the initial sequence-learning phase of the task. This impairment was not present
in the paroxetine-treated MDD group. On the other hand, paroxetine-treated patients with
MDD, but not medication-naïve patients with MDD, showed impairment on the
generalization phase in which the previously learned rules needed to be applied in a novel
context, a function that has been attributed to the medial temporal lobe in a previous study
using this task (Nagy et al., 2007a).
The results of our study indicate that medication-naïve patients with MDD show a similar
cognitive profile to medication-naïve patients with Parkinson’s disease who were previously
tested on this same task (Nagy et al., 2007a), with both patient groups showing impaired
learning but spared generalization. This observation might be attributed to the effect of both
disorders on striatal dopamine (Kish et al., 1988; McCabe et al., 2010; Walter et al., 2007)
as well as a deficit in raphe serotonin (Gervais and Rouillard, 2000; Guiard et al., 2008).
Furthermore, there is an overlap between MDD and Parkinson’s disease, where patients with
MDD are at a higher risk to develop Parkinson’s disease later in life (Leentjens et al., 2003;
Schuurman et al., 2002), whereas 50% of patients with PD develop MDD during the course
of the disease (Cummings, 1992; Veiga et al., 2009). However, it is not clear whether this
overlap between the two disorders is a consequence of dopaminergic dysfunction alone, or it
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is a mixture of both serotonergic and dopaminergic effects (Delaville et al., 2012; Kitaichi et
al., 2010), which could also have caused the deficit in sequence learning. To dissociate the
involvement of serotonergic and dopaminergic systems, studies comparing dopaminergic
and serotonergic antidepressants are required and will be an important direction for future
research.
SSRIs are the first line of treatment for MDD, due to their well-documented mood-elevating
effect (Belmaker, 2008). It is believed that SSRIs achieve their therapeutic outcome by
increasing synaptic concentrations of not only serotonin, but also dopamine and
norepinephrine (Dunlop and Nemeroff, 2007; Nutt, 2006). SSRI-treated patients in our study
received paroxetine mono-therapy to treat their depressive symptoms. Compared to
medication-naïve patients with MDD and HC, paroxetine-treated patients with MDD
showed no impairment on the sequence-learning phase. This might be a result of paroxetine
increasing serotonin and dopamine concentrations, leading to a reduction of reward learning
deficit (Cools et al., 2011; Stoy et al., 2011). Minimizing the deficit in reward learning in
paroxetine-treated patients with MDD could explain the remediation of learning on the
sequence-learning phase, as compared to the medication-naïve patients with MDD who
showed impairment on the same phase similar to that seen in medication-naïve patients with
Parkinson’s disease (Nagy et al., 2007a; Nagy et al., 2007b; Shohamy et al., 2005).
However, the remediation of the sequence-learning deficit in the paroxetine-treated group
could be attributed to diminished neural processing of reward and punishment feedback
during SSRI treatment, bringing reward and punishment into balance (McCabe et al., 2010).
MDD impairs cognitive function at multiple levels, and SSRIs also affect many other
neurotransmitter systems that could contribute to the changes in behavioral performance
(Belmaker and Agam, 2008),]. It is worth noting that the severity of depressive symptoms,
as reflected by BDI-II scores, significantly correlates with the number of errors on the
sequence-learning phase of the cognitive task, such that the more depressed people
performed most poorly on this learning phase. This is similar to the results we obtained in a
previous study using a learning and generalization task with patients with Parkinson’s
disease (Herzallah et al., 2010).
LIMITATIONS AND FUTURE DIRECTIONS
An important limitation of the current study is that the different severity of depressive
symptoms in SSRI-treated vs. medication-naïve patients might have contributed to the
difference between the groups. We did not have access to SSRI-treated patients’ BDI-II
scores before they were placed on the SSRI regimen. Therefore, it is impossible to conclude
that the observed behavioral effects originate from the medication alone. However, we
matched the different groups on almost all measures of neuropsychological and
neuropathology tests we used in this study.
On the generalization phase, the performance of medication-naïve patients with MDD was
not significantly different from that of HC subjects. In contrast, paroxetine-treated patients
with MDD were selectively impaired on the generalization phase, resembling patients with
amnestic mild cognitive impairment previously studied using this same task (Nagy et al.,
2007a).
Although some previous work has argued that there are “hippocampal-related” cognitive
deficits in patients with MDD, and that SSRI administration remediates these deficit
(Vythilingam et al., 2004), more recent evidence suggests that there are no volumetric
difference at the level of the hippocampus between patients with MDD and normal healthy
controls (Kroes et al., 2011; Vythilingam et al., 2004). This finding does not rule out non-
volumetric dysfunctions, but we argue that most prior research studies of learning and
memory in MDD have used the delayed paragraph recall test (Vythilingam et al., 2004)
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which is (i) not specific to the medial temporal lobe, as performance can be affected by
disrupted frontal function (Loewenstein et al., 2009), and (ii) not sufficiently sensitive to
mild degrees of hippocampal atrophy or dysfunction (Loewenstein et al., 2009; Myers et al.,
2002).
One possible explanation of our results – and their seeming paradoxical conflict with these
past other reports -- might be that SSRI administration results in hippocampal dysfunction
via induction of excessive neurogenesis in the dentate gyrus (Meltzer et al., 2005; Ming and
Song, 2011). This, of course, is only a conjecture. However, some studies suggest that SSRI-
induced neurogenesis produces cells that are characteristically different than cells that are
naturally generated in the dentate gyrus (Kobayashi et al., 2010; Liu et al., 2011; O’Leary et
al., 2009). These immature newborn cells have different functions than mature cells (Kesner
et al., 2004); they are more excitable (Snyder et al., 2001) and tend to inhibit mature neurons
in the dentate gyrus (Kobayashi et al., 2010), therefore leading to impaired function of the
dentate gyrus in pattern separation of input to the dentate gyrus (Ming and Song, 2011).
Moreover, recent evidence in the animal literature also suggests that hippocampal
neurogenesis can impair memory retrieval in a radial arm maze (Saxe et al., 2007). Thus, it
is possible that the production of immature cells in the hippocampal network as a result of
SSRI administration negatively impact memory processes (Saxe et al., 2007). Future
research, of course, is needed to evaluate this hypothesis. The near-significant negative
correlation between errors on the generalization phase and WAIS-R digit-span scores (a
measure of short-term memory) indicates that those who were most impaired on
generalization (more errors) had the worst scores on short-term memory (Figure 3-B), which
is in line with previous literature that suggests a negative effect of dentate gyrus
neurogenesis on some types of memory (Aimone et al., 2009; Saxe et al., 2007; Weisz and
Argibay, 2009). A larger study will be required to see if this trend holds consistently and
significantly.
Another possible way in which SSRIs could affect hippocampal function via their impact on
rapid eye movement (REM) sleep. Studies suggest that SSRI administration suppresses
REM sleep (Brooks and Gershon, 1977; Ross et al., 1990), which impairs hippocampal-, but
not striatal-, dependent learning {Watts, 2012 #4254;Fogel, 2007 #4255;Hennevin, 1995
#4256;Hennevin, 2007 #4257}. This is in agreement with our findings where SSRI-treated
patients with MDD show deficit on the hippocampal-dependent generalization phase, but
improved striatal-dependent learning phase of the cognitive task we used. However, it is still
unclear how SSRI administration leads to REM suppression and related cognitive deficit.
More research is required to disentangle MDD-related from sleep-related cognitive deficits,
and further explore the role of SSRIs in subsequent cognitive changes. It will be particularly
important in future research to better understand how individual differences in SSRI-related
changes in REM correlate with SSRI-mediated changes in both clinical symptoms and
cognitive function.
Another possible interpretation of our results is that paroxetine, the SSRI that was used to
treat MDD in our sample, has a weak anti-nicotinic anticholinergic effect (Fortin et al.,
2011; Mertens and Pintens, 1988). The hippocampus has a high concentration of nicotinic
cholinergic receptors (Martin and Aceto, 1981). Previous studies have shown that using
multiple SSRIs with anticholinergic properties might impair hippocampal dependent
memory functions (Fortin et al., 2011; Herzallah et al., 2010). Thus, this weak
anticholinergic effect of paroxetine could have contributed to the deficit we observe in the
generalization phase of cognitive task in the SSRI treated MDD patients. However,
compared to other anticholinergic agents, paroxetine has been found to have a relatively
weak anticholinergic effect (Chew et al., 2008), suggesting that this explanation is unlikely.
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We base some of our interpretations of the current study by drawing on findings obtained
using the same task in patient populations with amnestic mild cognitive impairment and
Parkinson’s disease (Nagy et al., 2007a; Nagy et al., 2007b; Shohamy et al., 2005).
However, various studies suggest that amnestic mild cognitive impairment affects many
brain systems, other than the medial temporal lobe, and these might contribute to the deficit
we found in the generalization phase of the cognitive task (Van Dam et al., 2013). Further,
Parkinson’s disease has been shown to affect several systems in the brain other than the
nigrostriatal dopamine system (Jellinger, 1991; Mann and Yates, 1983). Subsequently,
generalizing earlier results to our findings in MDD might require further research into the
overlapping biological correlates between these disorders.
One major limitation to our study is the between-subject design, where the mediation-naïve
and the SSRI-treated MDD patients are different individuals. Given the heterogeneity of
MDD, and how various subtypes of MDD differ with regards to cognitive function, the
current result might be confounded by between-subject variability originating from factors
other than MDD and SSRI administration. We did, of course, try to control for that in the
current study by recruiting melancholic MDD patients only, and by matching the two groups
on various neuropsychological and demographic measures as described earlier. However,
future work ought to address this issue through within-subject methodologies, examining the
same MDD patients on and off medication.
Another limitation of the current study is the low number of recruited subjects. This
becomes evident in the correlational analyses where we collapsed all groups together to
investigate correlations within the larger group. However, given that the focus of the current
study is task-measured cognitive function, all a priori power analyses indicated the need for
14 subjects per group to achieve power levels higher than 90%, which confirms the
sufficiency of the number of subjects in the analysis of our primary cognitive results. Future
larger studies, however, should address these imitations and better control for possible
confounding variables. Despite these power limitations, we found a double dissociation
between medication naïve and SSRI-treated patients with MDD in learning and
generalization.
In sum, our results show that SSRIs have both enhancing and deleterious effects on
cognition in MDD. To our knowledge, this is the first study to dissociate the effects of MDD
and SSRI treatment on cognitive function. Our results examine the effects of chronic (longer
than eight weeks) administration of SSRIs. However, there is still much to explore regarding
the time course of the effects of SSRIs on cognition, and how this time course might relate
to the time course of remediation of depressive symptoms. Moreover, given the
heterogeneity of MDD and the wide range of individual differences among people suffering
from MDD, further research is needed to better characterize the cognitive correlates of
various subcategories of MDD. Additional research is also needed to study other
antidepressants in use, such as selective norepinephrine reuptake inhibitors (SNRIs),
tricyclic antidepressants, and dopamine agonists. In addition, the cognitive correlates of
other treatment modalities, such as cognitive behavioral therapy, repetitive TMS, and
electroconvulsive therapy, and how that might interact with antidepressant treatment
regimen also needs further investigation.
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Figure 1.
Illustration of the Sequence Learning with Context Shift Task.
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Figure 2.
Computer-based cognitive task results. (A) The mean numbers of errors on the sequence-
learning phase of the task (chain steps A–D) (±SEM). (B) The mean numbers of errors on
the generalization with context-shift phase (±SEM). MDD are medication-naïve patients
with MDD, MDD-T are SSRI-treated patients with MDD, HC are healthy controls.
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Figure 3.
(A) Correlation between BDI-II scores and the numbers of errors on the sequence-learning
phase of the task (chain steps A–D), Pearson’s r=0.360, N=51, p=0.009. (B) Correlation
between WAIS-R digit-span scores and the number of errors on the context-shift
generalization phase, Pearson’s r=−0.245, N=51, p=0.083.
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Table 2
The Sequence Learning with Context-Shift Learning Paradigm
Phase Description Doors shown Correct response
Practice Cue-association P1P2P3 P1→reward
Sequence-Learning Chain step A A1A2A3 A1→ reward
Chain step B B1B2B3 B1 →A1 → reward
Chain step C C1C2C3 C1 →B1 →A1 → reward
Chain step D D1D2D3 D1 →C1 →B1 →A1 → reward
Context-Shift Generalization Example generalization trial D1B1X1 D1 →C1 →B1 →A1 → reward
Retest Cue-association Y1Y2Y3 Y1→ reward
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